Obesity and Overweight: The "Elephant in the Room" That We Can No Longer Ignore: Time to SELECT Treatments

Overview

Journal High Blood Press Cardiovasc Prev

Specialty Cardiology & Vascular Diseases

Date 2024 Feb 4

PMID 38310634

Authors

Armando Ferrera

Giovanna Gallo

Massimo Volpe

Affiliations

Soon will be listed here.

Citing Articles

Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management.

Gallo G, Desideri G, Savoia C Nutrients. 2024; 16(16).

PMID: 39203917 PMC: 11356794. DOI: 10.3390/nu16162781.

References

Wharton S, Davies M, Dicker D, Lingvay I, Mosenzon O, Rubino D . Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2021; 134(1):14-19. DOI: 10.1080/00325481.2021.2002616. View

Visseren F, Mach F, Smulders Y, Carballo D, Koskinas K, Back M . 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34):3227-3337. DOI: 10.1093/eurheartj/ehab484. View

Volpe M, Borghi C, Cameli M, Cianflone D, Cittadini A, Maggioni A . How cardiologists can manage excess body weight and related cardiovascular risk. An expert opinion. Int J Cardiol. 2023; 381:101-104. DOI: 10.1016/j.ijcard.2023.03.054. View

Jastreboff A, Aronne L, Ahmad N, Wharton S, Connery L, Alves B . Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022; 387(3):205-216. DOI: 10.1056/NEJMoa2206038. View

Volpe M, Gallo G . Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). Front Cardiovasc Med. 2023; 10:1136340. PMC: 10040794. DOI: 10.3389/fcvm.2023.1136340. View

Ferrera A, Battistoni A, Volpe M . Obesity: an overlooked player in cardiological practice and the need for urgent action. Eur Heart J. 2024; 45(19):1692-1694. DOI: 10.1093/eurheartj/ehad875. View

Koliaki C, Dalamaga M, Liatis S . Update on the Obesity Epidemic: After the Sudden Rise, Is the Upward Trajectory Beginning to Flatten?. Curr Obes Rep. 2023; 12(4):514-527. DOI: 10.1007/s13679-023-00527-y. View

Volpe M, Gallo G, Modena M, Ferri C, Desideri G, Tocci G . Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention. High Blood Press Cardiovasc Prev. 2022; 29(2):91-102. PMC: 8756172. DOI: 10.1007/s40292-021-00503-4. View

Wilding J, Batterham R, Calanna S, Davies M, Van Gaal L, Lingvay I . Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021; 384(11):989-1002. DOI: 10.1056/NEJMoa2032183. View

10.

Volpe M, Borghi C, Cameli M, Cianflone D, Cittadini A, Maggioni A . [Eight reasons why cardiologists should not overlook the problem "obesity". Expert opinion for clinical practice]. G Ital Cardiol (Rome). 2023; 24(9):677-691. DOI: 10.1714/4084.40678. View

11.

Ferrera A, Battistoni A, Lanza O, Rossi C, Tocci G, Volpe M . Low Perception of Obesity as a Pathological Condition Among Italian Cardiologists. High Blood Press Cardiovasc Prev. 2023; 30(4):351-356. DOI: 10.1007/s40292-023-00588-z. View

12.

Boutari C, Mantzoros C . A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022; 133:155217. PMC: 9107388. DOI: 10.1016/j.metabol.2022.155217. View

13.

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M . A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015; 373(1):11-22. DOI: 10.1056/NEJMoa1411892. View

14.

Bovet P, Chiolero A, Gedeon J . Health Effects of Overweight and Obesity in 195 Countries. N Engl J Med. 2017; 377(15):1495-6. DOI: 10.1056/NEJMc1710026. View

15.

Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. DOI: 10.1056/NEJMoa1607141. View

16.

Lincoff A, Brown-Frandsen K, Colhoun H, Deanfield J, Emerson S, Esbjerg S . Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023; 389(24):2221-2232. DOI: 10.1056/NEJMoa2307563. View